论文部分内容阅读
目的探讨抑癌基因在前列腺癌组织中的表达及临床意义。方法应用免疫组织化学方法，检测２５例前列腺癌中ｐ５３和ｐ１６基因蛋白产物的表达。结果ｐ５３蛋白阳性率为３２％（８／２５），明显高于良性前列腺增生（Ｐ＜０．０５），并在低分化肿瘤中表达高（Ｐ＝０．０４０３）；在临床分期Ⅲ～Ⅳ期癌中表达升高（Ｐ＜０．０５）。ｐ１６的失活率４４％（１１／２５），也是低分化组高于高分化组（Ｐ＜０．０５）。并发现４例低分化癌中有ｐ５３和ｐ１６共同异常。结论ｐ５３和ｐ１６基因的异常表达均与前列腺癌的形成和恶性程度有关，但两者之间是否具有协同作用尚待进一步证明。
Objective To investigate the expression of tumor suppressor gene in prostate cancer and its clinical significance. Methods Immunohistochemistry was used to detect the protein expression of p53 and p16 in 25 cases of prostate cancer. Results The positive rate of p53 protein was 32% (8/25), significantly higher than that of benign prostatic hyperplasia (P <0.05) and high expression in poorly differentiated tumors (P = 0.0403). In the clinical stage Ⅲ ~ Ⅳ Stage cancer (P <0.05). The inactivation rate of p16 was 44% (11/25), which was also lower in poorly differentiated group than in well differentiated group (P <0.05). Four cases of poorly differentiated carcinoma were found to have p53 and p16 common abnormalities. Conclusion The abnormal expression of p53 and p16 genes are both related to the formation of prostate cancer and the degree of malignancy. However, it is yet to be further proved whether there is a synergistic effect between the two.